ANALGETIKA MIT VERZÖGERTER WIRKSTOFFABGABE

A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiologically labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ASHTON, PAUL, CYNKOWSKI, TADEUSZ, SMITH, THOMAS, MICKUNAS, EDMUND, CYNKOWSKA, GRAZYNA
Format:	Patent
Sprache:	ger
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	ASHTON, PAUL CYNKOWSKI, TADEUSZ SMITH, THOMAS MICKUNAS, EDMUND CYNKOWSKA, GRAZYNA
description	A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiologically labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group consisting of an opioid or a no-opioid compound through a physiologically labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamido linkages. Suitable linkers include endogenous carboxylate, amido, and sulfonamido moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamido linkages.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ATE506064TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ATE506064TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ATE506064TT13</originalsourceid><addsrcrecordid>eNrjZNB29HP0cXcN8fR2VPD1DFEIcw2KOjzN3TUoxDVIIdwzyDs4xN_NzdHJ3dHJlYeBNS0xpziVF0pzMyi6uYY4e-imFuTHpxYXJCan5qWWxDuGuJoamBmYmYSEGBoTowYA7-0mcw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANALGETIKA MIT VERZÖGERTER WIRKSTOFFABGABE</title><source>esp@cenet</source><creator>ASHTON, PAUL ; CYNKOWSKI, TADEUSZ ; SMITH, THOMAS ; MICKUNAS, EDMUND ; CYNKOWSKA, GRAZYNA</creator><creatorcontrib>ASHTON, PAUL ; CYNKOWSKI, TADEUSZ ; SMITH, THOMAS ; MICKUNAS, EDMUND ; CYNKOWSKA, GRAZYNA</creatorcontrib><description>A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiologically labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group consisting of an opioid or a no-opioid compound through a physiologically labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamido linkages. Suitable linkers include endogenous carboxylate, amido, and sulfonamido moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamido linkages.</description><language>ger</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2011</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110515&DB=EPODOC&CC=AT&NR=E506064T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20110515&DB=EPODOC&CC=AT&NR=E506064T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ASHTON, PAUL</creatorcontrib><creatorcontrib>CYNKOWSKI, TADEUSZ</creatorcontrib><creatorcontrib>SMITH, THOMAS</creatorcontrib><creatorcontrib>MICKUNAS, EDMUND</creatorcontrib><creatorcontrib>CYNKOWSKA, GRAZYNA</creatorcontrib><title>ANALGETIKA MIT VERZÖGERTER WIRKSTOFFABGABE</title><description>A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiologically labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group consisting of an opioid or a no-opioid compound through a physiologically labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamido linkages. Suitable linkers include endogenous carboxylate, amido, and sulfonamido moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamido linkages.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2011</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNB29HP0cXcN8fR2VPD1DFEIcw2KOjzN3TUoxDVIIdwzyDs4xN_NzdHJ3dHJlYeBNS0xpziVF0pzMyi6uYY4e-imFuTHpxYXJCan5qWWxDuGuJoamBmYmYSEGBoTowYA7-0mcw</recordid><startdate>20110515</startdate><enddate>20110515</enddate><creator>ASHTON, PAUL</creator><creator>CYNKOWSKI, TADEUSZ</creator><creator>SMITH, THOMAS</creator><creator>MICKUNAS, EDMUND</creator><creator>CYNKOWSKA, GRAZYNA</creator><scope>EVB</scope></search><sort><creationdate>20110515</creationdate><title>ANALGETIKA MIT VERZÖGERTER WIRKSTOFFABGABE</title><author>ASHTON, PAUL ; CYNKOWSKI, TADEUSZ ; SMITH, THOMAS ; MICKUNAS, EDMUND ; CYNKOWSKA, GRAZYNA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ATE506064TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2011</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ASHTON, PAUL</creatorcontrib><creatorcontrib>CYNKOWSKI, TADEUSZ</creatorcontrib><creatorcontrib>SMITH, THOMAS</creatorcontrib><creatorcontrib>MICKUNAS, EDMUND</creatorcontrib><creatorcontrib>CYNKOWSKA, GRAZYNA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ASHTON, PAUL</au><au>CYNKOWSKI, TADEUSZ</au><au>SMITH, THOMAS</au><au>MICKUNAS, EDMUND</au><au>CYNKOWSKA, GRAZYNA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANALGETIKA MIT VERZÖGERTER WIRKSTOFFABGABE</title><date>2011-05-15</date><risdate>2011</risdate><abstract>A pharmaceutically active inventive compound comprises two independently active analgesic moieties covalently conjoined through a physiologically labile linker. A preferred embodiment comprises an opioid, such as morphine, covalently linked to at least one analgesic compound selected from the group consisting of an opioid or a no-opioid compound through a physiologically labile linker. Suitable covalent linkers are covalently bonded to the two independently active analgesic compounds through one or more lactone, lactam, or sulfonamido linkages. Suitable linkers include endogenous carboxylate, amido, and sulfonamido moieties, and exogenous moieties that form the aforementioned lactone, lactam or sulfonamido linkages.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	ger
recordid	cdi_epo_espacenet_ATE506064TT1
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	ANALGETIKA MIT VERZÖGERTER WIRKSTOFFABGABE
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T19%3A35%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ASHTON,%20PAUL&rft.date=2011-05-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EATE506064TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true